Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
| العنوان: | Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease |
|---|---|
| المؤلفون: | Mary Akinola, Milos D. Ikonomovic, Marc Agronin, Jiong Shi, Adrian Smith, Joel Ross, Craig Curtis, Michelle Zanette, Marwan N. Sabbagh, Stephen Salloway, Yavir M. Escovar, Dietmar Rudolf Thal, Teresa Villena, Jose Gamez, Upinder Singh, Ranjan Duara, Carl H. Sadowsky, Adam S. Fleisher, Thomas G. Beach, Gill Farrar, Rik Vandenberghe, Paul Sherwin, Kirk A. Frey, Zuzana Walker, Andrea Bozoki, Christopher Buckley, Arvinder Hunjan |
| المصدر: | Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring |
| بيانات النشر: | Elsevier, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Pathology, medicine.medical_specialty, Amyloid, Amyloid pet, Neuroimaging, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Sensitivity, mental disorders, medicine, Senile plaques, Diagnostic, Postmortem brain, medicine.diagnostic_test, Alzheimer's disease, Psychiatry and Mental health, Positron emission tomography, Amyloid PET, [18F]Flutemetamol, Specificity, Neurology (clinical), Autopsy, Psychology, Thal phasing, Positron Emission Tomography Scan, 030217 neurology & neurosurgery |
| الوصف: | Introduction Performance of the amyloid tracer [18F]flutemetamol was evaluated against three pathology standard of truth (SoT) measures including neuritic plaques (CERAD “original” and “modified” and the amyloid component of the 2012 NIA-AA guidelines). Methods After [18F]flutemetamol imaging, 106 end-of-life patients who died underwent postmortem brain examination for amyloid plaque load. Blinded positron emission tomography scan interpretations by five independent electronically trained readers were compared with pathology measures. Results By SoT, sensitivity and specificity of majority image interpretations were, respectively, 91.9% and 87.5% with “original CERAD,” 90.8% and 90.0% with “modified CERAD,” and 85.7% and 100% with the 2012 NIA-AA criteria. Discussion The high accuracy of either CERAD criteria suggests that [18F]flutemetamol predominantly reflects neuritic amyloid plaque density. However, the use of CERAD criteria as the SoT can result in some false-positive results because of the presence of diffuse plaques, which are accounted for when the positron emission tomography read is compared with the 2012 NIA-AA criteria. Highlights • Determination of the accuracy of [18F]flutemetamol image read against Aβ at autopsy. • High sensitivity and specificity to 3 neuropathologic criteria as Standards of Truth. • Images are 100% specific when the SoT reflects both neuritic and diffuse plaques. • This study has the largest autopsy validation cohort for Aβ PET tracers to date. |
| اللغة: | English |
| تدمد: | 2352-8729 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0842f2de9d6a97e19f557c0964137a9 http://europepmc.org/articles/PMC5536824 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....f0842f2de9d6a97e19f557c0964137a9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23528729 |
|---|